William N. Washburn

TL;DR: SGLT2 inhibiting compounds are provided having the formula (I) wherein n is 0, 1 or 2; A is formula (a) or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO2, bearing substituents R?3 and R4; and R1 to R4? are as defined in this article.

TL;DR: Current evidence suggests that SGLT2 inhibitors have similar efficacy in terms of glycemic control and also demonstrate benefits beyond glycemic reductions, including reductions in body weight and modest reductions in blood pressure.

TL;DR: It is demonstrated that the proper relationship of a 4'-substituted benzyl group to a beta-1C-phenylglucoside is important for potent and selective SGLT2 inhibition and it promotes glucosuria when administered in vivo.

TL;DR: Czernecki et al. as mentioned in this paper showed that triisopropylsilane as a reducing agent gives a 4:1 mixture of anomers (β:α) for tetra-O-benzyl-protected 1C-phenylglucoside.

TL;DR: In this article, a practical synthesis of the SGLT-2 inhibitor β-C-aryl-d-glucoside (1) has been developed using 2,3,4,6-tetra-Otrimethlysilyl-dglucano-1,5-lactone as the key chiral building block, prepared efficiently from commercially available, inexpensive raw materials, d-gluconolactone and trimethylsilyl chloride.